Vor Biopharma (VOR)
Develops licensed telitacicept for autoimmune diseases outside Greater China.
Something off on this page? Send us feedback.
Develops telitacicept, a BAFF/APRIL-targeting autoimmune therapy licensed from RemeGen for territories outside Greater China. The clinical-stage company reset its business after winding down former cancer programs, and current development centers on a global Phase 3 trial in primary Sjögren’s disease.
Develops telitacicept, a BAFF/APRIL-targeting therapy licensed from RemeGen for autoimmune diseases outside Greater China. A global Phase 3 trial in primary Sjögren’s disease is underway, making telitacicept the center of its post-restructuring clinical program for autoimmune-disease development.
The business was reset after the company wound down its former cell-and-genome-engineering cancer programs. The former platform was discontinued. RemeGen retains rights in mainland China, Hong Kong, Macau, and Taiwan, so development and commercialization outside that territory depend on the license. Operations are based in Boston, while the company’s common stock trades on Nasdaq.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 12, 2026 | Wedbush | Reiterate | Rating: —Target: $18 | Target: $27 |
| May 14, 2026 | Wedbush | Reiterate | Rating: —Target: — | Target: $18 |
| Apr 15, 2026 | H.C. Wainwright | Target | Target: $55 | Target: $31 |
| Dec 23, 2025 | Robert W. Baird | Target | Target: $64 | Target: $46 |
| Oct 29, 2025 | H.C. Wainwright | Target | Target: $3 | Target: $55 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $466.1M · Total debt $2.9M · Total assets $481.1M · Shareholders' equity −$200.2M
- Revenue
- $0
- Operating income
- −$47.9M
- Net income
- −$62.8M
No dividends on record.
| Institutions | ≈ 89.74% | 48.63M shares | |
|---|---|---|---|
| 105 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.26% | 142.6K shares | |
| 7 holders · as of Apr 9, 2026 | |||
| Strategic holders | 16.61% | 9.00M shares | |
| 3 holders · as of May 15, 2026 | |||
| Adds to | 106.61% | ||
54.19M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (59.16M in the company's Sep 22, 2026 report, 54.19M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 106.61%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
TCG Crossover Management, LLCInstitution | 10.47% | 5.67M | as of Jun 30, 2026 |
Venrock Healthcare Capital Partners III, L.P.Institution | 9.38% | 5.08M | filed May 15, 2026 |
Verve Capital LimitedStrategic | 9.23% | 5.00M | filed May 15, 2026 |
FMR LLCInstitution | 9.10% | 4.93M | as of Jun 30, 2026 |
FCPM Iii Services B.V.Institution | 7.60% | 4.12M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 16, 2026 | Ra Capital Management, L.P. | 10 percent owner | −213 | $19.75 |
| Apr 22, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | −165,150 | $15.77 |
| Apr 20, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | −171,963 | $15.77 |
| Apr 17, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | −458,411 | $16.28 |
| Apr 15, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | −53,644 | $16.01 |
- argenx (ADR)
Commercialized FcRn therapy in gMG and a Sjögren’s trial
- Johnson & Johnson
FDA-approved FcRn blocker for antibody-positive gMG
- AstraZeneca (ADR)
Commercialized C5 inhibitors for antibody-positive gMG
- Novartis (ADR)
Phase 3 anti-BAFF therapy for primary Sjögren’s disease
- Amgen
Phase 3 CD40L blocker for primary Sjögren’s disease
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vor Biopharma | $22.31 | +1.92% | $1.19B | — | — | — | — |
| argenx (ADR) | $968.45 | −2.00% | $61.45B | 37.7 | — | 10.2 | +197.0% |
| Johnson & Johnson | $269.57 | +0.04% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| AstraZeneca (ADR) | $168.65 | +0.33% | $260.70B | 25.2 | 15.9 | 4.2 | +6.4% |
| Novartis (ADR) | $141.57 | +0.42% | $267.96B | 21.3 | 15.1 | 4.8 | +0.9% |
| Amgen | $409.87 | +4.25% | $212.19B | 24.4 | 17.5 | 5.6 | +9.7% |
| Median | 25.2 | 16.7 | 5.6 | +6.6% |